Global InformationCXL 1020 information
CXL 1020 is an experimental drug that is being investigated as a treatment for acute decompensated heart failure. CXL 1020 functions as a nitroxyl donor; nitroxyl is the reduced, protonated version of nitric oxide.[1] Nitroxyl is capable of enhancing left ventricular contractility without increasing heart rate by modifying normal Ca2+ cycling through the sarcoplasmic reticulum[2] as well as increasing the sensitivity of cardiac myofilaments to Ca2+.[3]
- ^ Del Rio, Carlos; Yukie Ueyama; Robert L. Hamlin; John Reardon; Reza Mazhari (April 2011). "CXL-1020, A Novel Hno Donor, Decreases Myocardial Loading and Enhances Load-Independent Lusitropy and Inotropy Via A ?-Ar/Ace Independent Mechanism". JACC. 57 (17): E326. doi:10.1016/s0735-1097(11)60326-4.
- ^ Kohr, Mark; Nina Kaludercic; Carlo Tocchetti; Wei Dong Gao; David Kass; Paul Janssen; Nazareno Paolocci; Mark Ziolo (March 2011). "Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling". Frontiers in Bioscience. E2 (2): 614–626. doi:10.2741/e118. PMC 3057191. PMID 20036906.
- ^ Dai, Tieying; Ye Tian; Carlo Tocchetti; Tatsuo Katori; Anne Murphy; David Kass; Nazareno Paolocci; Wei Dong Gao (2007). "Nitroxyl increases force development in rat cardiac muscle". Journal of Physiology. 580 (3): 951–960. doi:10.1113/jphysiol.2007.129254. PMC 2075441. PMID 17331988.